IMPORTANT MILESTONE REACHED – PHASE IIB-STUDY FULLY RECRUITED
The last patient has been recruited in the ongoing phase IIb clinical trial of STA363 for chronic disc-related low back pain. Recruitment is thereby completed. The patients will be followed for 12 months after inclusion. Final results from the study are expected to be available in Q4 2023 after the Company has compiled and analyzed data from all treated patients in the study.
Read more in the Press Release
Latest press releases
Kalqyl publishes analysis of Stayble Therapeutics
Stayble Therapeutics AB (“Stayble” or the “Company”) has recently entered into an agreement with the analysis company Kalqyl AB (“Kalqyl”) which has now published the first analysis of Stayble.
CEO buys shares in Stayble Therapeutics
Stayble Therapeutics AB (”Stayble” or the ”Company”) announces today that the Company’s CEO Andreas Gerward has purchased 15,000 shares in the Company for a total value of 73 350 SEK. The shares have been purchased in the open market.
Financial reports
Get all the latest news
Or connect with us on linkedin
Bridging the therapeutic gap
About 30% of all patients with discogenic cLBP are helped by therapy such as analgesics and physiotherapy, and only 1% undergo spine surgery. Stayble’s product STA363 will bridge the gap between conservative and radical therapy to the benefit of millions of patients presently left on their own to cope with sustained and disabling pain.
Our market
Treating the root cause of the disease. Not just the symptoms.
Instead of costly or time-consuming procedures, such as spinal fusion or long-term physiotherapy, our cLBP treatment is an easily performed, single injection procedure that stabilises the disc by transforming it to connective tissue. Unlike any other currently available treatment, this has the potential to permanently attenuate the pain significantly faster than surgical intervention.
Healthy disc
An intervertebral disc consists of two main parts: the disc centre and the wall. The disc centre consists largely of a highly hydrated gel together with nucleus pulposus cells and fibroblasts.
DEGENERATED UNTREATED DISC
When a disc degenerates it becomes less stable and proinflammatory substances formed during the degenerative process can leak from the inner core of the disc. Pain-sensing nerves within and outside the wall of the disc are activated. These processes cause back pain.
Treated disc
By injecting STA363 directly into the degenerated intervertebral disc, the cells are triggered to produce collagen and the damaged disc is transformed into connective tissue. This helps restabilise the intervertebral segment and reduces leakage of proinflammatory substances.
LET’S MEET UP
We are participating in several conferences and industry events every year. Please do not hesitate to contact us to meet up.
Upcoming eventsNo events planned at the moment
Get in touch
We are always looking for passionate people who are interested in joining us to help realizing our vision. Please leave your contact details and we will get back to you shortly.
info@stayble.se